ATE505488T1 - Modulator von coagulationskaskaden und fibrinolytischen kaskaden - Google Patents

Modulator von coagulationskaskaden und fibrinolytischen kaskaden

Info

Publication number
ATE505488T1
ATE505488T1 AT06736060T AT06736060T ATE505488T1 AT E505488 T1 ATE505488 T1 AT E505488T1 AT 06736060 T AT06736060 T AT 06736060T AT 06736060 T AT06736060 T AT 06736060T AT E505488 T1 ATE505488 T1 AT E505488T1
Authority
AT
Austria
Prior art keywords
cascades
modulator
fibrinolytic
coagulation
wound
Prior art date
Application number
AT06736060T
Other languages
English (en)
Inventor
James Morrissey
Stephanie Smith
Roberto Docampo
Nicola Mutch
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Application granted granted Critical
Publication of ATE505488T1 publication Critical patent/ATE505488T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06736060T 2005-03-04 2006-02-23 Modulator von coagulationskaskaden und fibrinolytischen kaskaden ATE505488T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65877605P 2005-03-04 2005-03-04
PCT/US2006/006642 WO2006096345A2 (en) 2005-03-04 2006-02-23 Coagulation and fibrinolytic cascades modulator

Publications (1)

Publication Number Publication Date
ATE505488T1 true ATE505488T1 (de) 2011-04-15

Family

ID=36648781

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06736060T ATE505488T1 (de) 2005-03-04 2006-02-23 Modulator von coagulationskaskaden und fibrinolytischen kaskaden

Country Status (8)

Country Link
US (2) US7682808B2 (de)
EP (1) EP1869082B1 (de)
JP (1) JP2008531692A (de)
CN (1) CN101184775A (de)
AT (1) ATE505488T1 (de)
CA (1) CA2600907C (de)
DE (1) DE602006021290D1 (de)
WO (1) WO2006096345A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008530208A (ja) * 2005-02-16 2008-08-07 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 万能前凝固薬
WO2006096345A2 (en) 2005-03-04 2006-09-14 The Board Of Trustees Of The University Of Illinois Coagulation and fibrinolytic cascades modulator
JP5073270B2 (ja) * 2006-11-14 2012-11-14 シスメックス株式会社 凝固検査用試薬及びその製造方法
US20090047366A1 (en) * 2007-08-15 2009-02-19 Bedard Robert L Inorganic Coagulation Accelerators for Individuals taking Platelet Blockers or Anticoagulants
US8821861B2 (en) * 2007-10-05 2014-09-02 The Board Of Trustees Of The University Of Illinois Fibrin sealant
US20100297257A1 (en) * 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant
DE102007062323A1 (de) * 2007-12-21 2009-06-25 Siemens Healthcare Diagnostics Products Gmbh Langzeitstabiles Thromboplastin-Reagenz
FR2934052B1 (fr) 2008-07-17 2011-11-25 Stago Diagnostica Dosage de l'activite du facteur tissulaire circulant
BR122021014783B1 (pt) 2008-12-19 2023-03-14 Baxalta GmbH Peptídeo que se liga a tfpi, uso do peptídeo, composição farmacêutica e método para purificação de tfpi
US8962563B2 (en) 2009-12-21 2015-02-24 Baxter International, Inc. TFPI inhibitors and methods of use
BRPI0924058B1 (pt) 2008-12-22 2021-08-17 Novo Nordisk A/S Anticorpos monoclonais, seus usos, bem como composição farmacêutica
SMT201700454T1 (it) 2010-03-01 2018-01-11 Bayer Healthcare Llc Anticorpi monoclonali ottimizzati contro inibitore della via di fattore tissutale (tfpi)
AU2011227714B2 (en) 2010-03-19 2014-09-04 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
BR112013005278B1 (pt) 2010-09-27 2019-07-09 Tissue Regenix Limited Produtos que comprendem matriz de tecido vascular xenogênico acelular e método de preparação de um tecido vascular xenogênico acelular
ES2970986T3 (es) 2013-03-08 2024-06-03 Univ California Nanopartículas inorgánicas funcionalizadas con polifosfato como composiciones hemostáticas y métodos de uso
DE102013222223A1 (de) 2013-10-31 2015-04-30 Bk Giulini Gmbh Blutstillendes Mittel enthaltend kristallines Polyphosphat
US9408871B2 (en) * 2013-11-08 2016-08-09 The University Of British Columbia Methods for inhibiting complement activation and uses thereof
US11112145B2 (en) 2014-09-24 2021-09-07 The Board Of Trustees Of The University Of Illinois Artificial platelets for treating catastrophic bleeding
JP7101351B2 (ja) 2016-04-28 2022-07-15 シスメックス株式会社 血液検体の分析方法、血液検体分析用試薬及び試薬キット、並びに血液検体分析装置
US11519917B2 (en) 2017-04-13 2022-12-06 The Regents Of The University Of Michigan Assay for quantifying polyphosphates
DK3897758T3 (da) 2018-12-20 2023-04-03 Bk Giulini Gmbh Middel til behandling af blødende sår
CN111856043A (zh) * 2020-08-28 2020-10-30 保定天岳生物工程有限公司 一种凝血酶原时间检测试剂盒

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2852341A (en) * 1954-08-20 1958-09-16 Victor Chemical Works Calcium polyphosphate and method of producing the same
DE1617733A1 (de) 1967-03-31 1971-04-08 Penicillin Ges Dauelsberg & Co Verfahren zur Herstellung eines Praeparates fuer die Behandlung schwer heilender Wunden und Eiterungen
ES431736A1 (es) 1973-11-13 1977-05-16 Behringwerke Ag Procedimiento para la preparacion de un agente para diagnos-tico para el proposito de efectuar el control de la capaci- dad de coagulacion de la sangre.
US4139619A (en) 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
DE3150596A1 (de) 1981-12-21 1983-06-30 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von gewebsthromboplastin
US5705477A (en) * 1982-09-24 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use
DE3413311A1 (de) 1984-04-09 1985-10-17 Behringwerke Ag, 3550 Marburg Reagenz zur bestimmung der thromboplastinzeit
US4684635A (en) 1984-05-11 1987-08-04 Norman Orentreich Compositions and methods for inhibiting the action of androgens
DE3516579A1 (de) 1984-11-19 1986-05-22 Boehringer Mannheim Gmbh, 6800 Mannheim Gerinnungstest auf teststreifen
US4874766A (en) * 1986-09-22 1989-10-17 Janssen Pharmaceutica N.V. Method of promoting wound-healing
ATE99543T1 (de) 1987-10-15 1994-01-15 Syntex Inc Pulverfoermige zubereitungen zur intranasalen verabreichung von polypeptiden.
US4865984A (en) 1988-02-08 1989-09-12 Mount Sinai School Of Medicine Of The City University Of New York Dynamic continuous flow enzyme reactor
US5632727A (en) * 1988-10-03 1997-05-27 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
EP0396733B1 (de) 1988-11-23 1994-01-05 Baxter Diagnostics Inc. Ausscheidungsverfahren für die herstellung von thromboplastinreagenzien
US5270451A (en) 1988-11-23 1993-12-14 Baxter Diagnostics Inc. Extraction method for preparing thromboplastin reagents
US5298599A (en) 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
US5472850A (en) 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
NL8902406A (nl) 1989-09-27 1991-04-16 Hendrik Coenraad Hemker Prof D Werkwijze voor het bepalen van de endogene trombinepotentiaal van plasma, en bloed alsmede een bij deze werkwijze te gebruiken kit.
US5169786A (en) 1989-12-19 1992-12-08 Ortho Diagnostic Systems, Inc. Method of determining levels of extrinsic and intrinsic clotting factors and protein c
US5314695A (en) * 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
US5374617A (en) 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
US5254350A (en) 1991-07-22 1993-10-19 Helena Laboratories Corporation Method of preparing a thromboplastin extract
US5338538A (en) 1991-07-29 1994-08-16 Pfizer Inc Prebrushing pyrophosphate-containing liquid oral compositions
DK0565665T3 (da) * 1991-10-04 1998-09-28 Dade Behring Inc Fremstilling af prothrombin-tidsreagenser ud fra rekombinant human faktor og syntetiske phospholipider
US5580744A (en) 1992-04-27 1996-12-03 Avocet Medical, Inc. Test article and method for performing blood coagulation assays
JP3368279B2 (ja) 1992-04-27 2003-01-20 ベックマン コールター，インコーポレイティド 血液凝固検定を行うためのテスト物品及び方法
US5358853A (en) 1992-08-03 1994-10-25 Akzo Av Liquid thromboplastin reagent
DE4243729A1 (de) 1992-12-23 1994-06-30 Behringwerke Ag Verfahren zur Reaktivierung von gereinigten Membranproteinen
JPH08512139A (ja) 1994-04-28 1996-12-17 デイド、インターナショナル、インコーポレイテッド プロトロンビン時間（ｐｔ）アッセイ用のキャリブレーター
US5418141A (en) 1994-05-06 1995-05-23 Avocet Medical, Inc. Test articles for performing dry reagent prothrombin time assays
AT403437B (de) 1995-02-15 1998-02-25 Immuno Ag Physiologisch aktive gewebefaktor-präparation
US5888968A (en) 1995-06-07 1999-03-30 Chiron Corporation TFPI formulation
PT1602667E (pt) 1995-06-07 2007-07-13 Searle Llc Formulação aquosa que compreende tfpi e agentes de solubilização
US5691380A (en) 1995-06-29 1997-11-25 The Procter & Gamble Company Stable n-acetylcysteine compositions and methods for treating human skin therewith
EP0803243B1 (de) 1996-04-24 2003-03-19 Pfizer Inc. Dentalwerkstoffe enthaltend Cyclodextrine und phenolische Verbindungen
US5858724A (en) * 1996-07-16 1999-01-12 Pel-Freez Recombinant rabbit tissue factor
US5787901A (en) * 1997-01-28 1998-08-04 Akzo Nobel N.V. Method for the measurement of blood coagulation properties with absorbent materials
AT405692B (de) 1997-03-27 1999-10-25 Immuno Ag Reagens zur bestimmung der aptt
ES2255157T3 (es) 1997-04-23 2006-06-16 Instrumentation Laboratory S.P.A. Reactivo de tiempo de protrombina basado en el factor tisular recombinante de conejo.
DE19720853A1 (de) 1997-05-17 1998-11-19 Dade Behring Marburg Gmbh Erhöhung der FVII Empfindlichkeit eines Thromboplastinreagenzes
US5968528A (en) 1997-05-23 1999-10-19 The Procter & Gamble Company Skin care compositions
US6258368B1 (en) * 1997-06-04 2001-07-10 The Procter & Gamble Company Antimicrobial wipes
WO1999005312A1 (fr) 1997-07-23 1999-02-04 Tokuyama Corporation Procede de determination de parametres de coagulation
AT409334B (de) 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
DE19749197A1 (de) 1997-11-07 1999-05-12 Dade Behring Marburg Gmbh Verfahren zur Bestimmung des antikoagulatorischen Potentials einer Probe
DE19749259A1 (de) 1997-11-07 1999-05-12 Dade Behring Marburg Gmbh Verfahren zur Herstellung von funktionalem rekombinantem Gewebsfaktor
US5928174A (en) * 1997-11-14 1999-07-27 Acrymed Wound dressing device
AU2878199A (en) 1998-02-27 1999-09-15 University Of North Carolina At Chapel Hill, The Mutant heparin cofactor ii
DE19811016A1 (de) 1998-03-13 1999-09-16 Dade Behring Marburg Gmbh Gebrauchsfertiges Prothrombinzeitreagenz auf der Basis von rekombinantem Gewebsfaktor
US6194394B1 (en) 1998-07-01 2001-02-27 Sigma-Aldrich Co. Coagulation controls for prothrombin time (PT) and activated partial thromboplastin time (APTT) assays
EP1127259B1 (de) 1998-10-07 2005-12-14 Trinity Biotech Manufacturing Ltd. Thromboplastin-reagenzien und verfahren zur herstellung und anwendung derselben
US6451610B1 (en) 1999-04-14 2002-09-17 International Technidyne Corporation Method and apparatus for coagulation based assays
US6284802B1 (en) 1999-04-19 2001-09-04 The Procter & Gamble Company Methods for regulating the condition of mammalian keratinous tissue
AUPQ002399A0 (en) 1999-04-28 1999-05-20 Australian National University, The Model membrane systems
US6733985B1 (en) 1999-05-19 2004-05-11 International Technidyne Corporation Preparation of stable liquid and dried synthetic prothrombin time reagents
EP1198179B1 (de) * 1999-07-22 2007-01-17 Astaris Llc Antimikrobielle polyphosphate in nahrungsmittelbehandlung
US6248353B1 (en) 1999-12-10 2001-06-19 Dade Behring Inc. Reconstitution of purified membrane proteins into preformed liposomes
US6187347B1 (en) * 2000-02-09 2001-02-13 Ecosafe, Llc. Composition for arresting the flow of blood and method
AU2001235365A1 (en) 2000-02-23 2001-09-03 Besst-Test Aps Method for correlating blood coagulation activity with markers in body fluids, e.g. urine
KR100338491B1 (ko) * 2000-03-30 2002-05-30 채수경 인중합체로 된 흉터 억제 및 상처 회복 촉진제
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US7622437B2 (en) * 2000-11-20 2009-11-24 The Board Of Trustees Of The University Of Illinois Tissue factor compositions and methods
EP1229048A1 (de) 2001-02-05 2002-08-07 International Reagents Corporation Thromboplastinreagenz und Verfahren zu dessen Herstellung
US6596543B2 (en) 2001-03-22 2003-07-22 Dade Behring Inc. Use of liposomes of defined composition and size for the preparation of prothrombin time reagents
US20030064414A1 (en) 2001-03-30 2003-04-03 Benecky Michael J. Rapid assessment of coagulation activity in whole blood
CA2470313A1 (en) 2001-12-21 2003-07-10 Michael Bech Jensen Liquid composition of modified factor vii polypeptides
DE60232017D1 (de) 2001-12-21 2009-05-28 Novo Nordisk Healthcare Ag Flüssige zusammensetzung aus faktor vii polypeptiden
US6746872B2 (en) 2002-01-16 2004-06-08 Lifescan, Inc. Control compositions and methods of use for coagulation tests
US20040084867A1 (en) 2002-06-28 2004-05-06 Xanthus Life Sciences, Inc. Individualization of therapy with anticoagulants
US7049087B2 (en) 2002-11-05 2006-05-23 Lifescan, Inc. Method for manufacturing a tissue factor-based prothrombin time reagent
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
KR100592513B1 (ko) 2003-06-12 2006-06-23 김홍렬 인중합체를 유효성분으로 함유하는 항산화용 약학적조성물 또는 건강식품
EP1682863B1 (de) 2003-09-22 2012-07-04 University Of North Carolina At Chapel Hill Lösliche phospholipide zur verwendung in gerinnungsfaktortests
US7148067B2 (en) 2004-08-31 2006-12-12 The Board Of Trustees Of The University Of Illinois Thromboplastin reagents
JP2008530208A (ja) * 2005-02-16 2008-08-07 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 万能前凝固薬
WO2006096345A2 (en) 2005-03-04 2006-09-14 The Board Of Trustees Of The University Of Illinois Coagulation and fibrinolytic cascades modulator
US7622737B2 (en) * 2007-07-11 2009-11-24 International Business Machines Corporation Test structures for electrically detecting back end of the line failures and methods of making and using the same
US20090053288A1 (en) * 2007-08-20 2009-02-26 Eskridge Jr E Stan Hemostatic woven fabric
US8821861B2 (en) * 2007-10-05 2014-09-02 The Board Of Trustees Of The University Of Illinois Fibrin sealant
US20100297257A1 (en) * 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant

Also Published As

Publication number Publication date
US7682808B2 (en) 2010-03-23
CA2600907A1 (en) 2006-09-14
WO2006096345A3 (en) 2006-11-30
CA2600907C (en) 2016-06-28
JP2008531692A (ja) 2008-08-14
CN101184775A (zh) 2008-05-21
WO2006096345A2 (en) 2006-09-14
US9597375B2 (en) 2017-03-21
US20100143492A1 (en) 2010-06-10
EP1869082B1 (de) 2011-04-13
EP1869082A2 (de) 2007-12-26
US20060198837A1 (en) 2006-09-07
DE602006021290D1 (de) 2011-05-26

Similar Documents

Publication Publication Date Title
ATE505488T1 (de) Modulator von coagulationskaskaden und fibrinolytischen kaskaden
SE0301882D0 (sv) New use I
MX2009004320A (es) Inhibidores de serina proteasa tipo tripsina, y su preparacion y uso.
NI200900205A (es) Nuevos péptidos inhibidores de la replicación del virus de la hepatitis c.
SE0301886D0 (sv) New use V
SE0301888D0 (sv) New use VII
NZ574653A (en) Solid dressing for treating wounded tissue
ATE544866T1 (de) Adamts13-haltige zusammensetzungen mit thrombolytischer wirkung
ATE551076T1 (de) Hämostyptikum zur topischen und inneren anwendung
ECSP10010310A (es) Nuevos compuestos y composiciones y métodos de uso
DE602005019319D1 (de) Zusammensetzungen mit ornithin und phenylacetat oder phenylbutyrat zur behandlung von hepatischer enzephalopathie
EP2547355A4 (de) Tfpi-hemmer und verwendungsverfahren dafür
WO2010071894A3 (en) Tfpi inhibitors and methods of use
CL2008001782A1 (es) Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.
NZ582556A (en) Pharmaceutical composition for treating wounds and related methods
DE602006010442D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von schmerzen
DE602006020775D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen
CL2009000367A1 (es) Compuestos derivados de tiofen-amidas, inhibidores de los factores de la coagulacion xa y trombina; procedimiento de preparacion; composicion farmaceutica; y uso en trastornos cardiovasculares, enfermedades tromboembolicas o restenosis.
BR112012028153A2 (pt) composição farmacêutica e método para o tratamento de hipertensão
EP2481429A3 (de) MMP-Aktivierte Gefässschädigende Mittel
ATE450187T1 (de) Verhinderung von hautlappennekrose in der plastischen chirurgie
EP2049101A4 (de) Substituiertes 4-aryl-chromen als caspasen-aktivator, apoptose-induktor und antivaskuläres mittel sowie seine verwendung
SE0301885D0 (sv) New use IV
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
SE0301884D0 (sv) New use III

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties